ANEB

Anebulo is a clinical-stage, single-asset story with zero revenue since inception and an accumulated deficit of $73.9M. Its entire value rests on selonabant, a CB1 antagonist for cannabis-induced toxicity that is still pre-Phase 3 — management explicitly states it does 'not anticipate generating revenue from product sales in the near term' and has now pivoted from adult ACI toward an IV pediatric formulation, a strategy shift that resets the development clock and adds execution risk to an already unapproved asset. This is a binary, unknowable outcome: there are no approved treatments in the category (a plus for the market thesis) but also no de-risked Phase 3 data, and unfavorable trial results would gut the equity.

The balance sheet is the one genuine bright spot and the reason this is 'avoid' rather than 'sell.' Liabilities are just $488K against $11.7M equity (0.04x liabilities/equity) and $11.6M cash — essentially debt-free with cash up 275.8% YoY after a raise. But that cash sits against a -$6.35M operating burn and management's own warning that it 'will need to raise additional capital' and expects 'significant losses' as it funds Phase 3; roughly 1.5–2 years of runway before another dilutive raise. Shares already grew 58.4% YoY to 41.1M, so existing holders should expect their stake to keep shrinking.